The third nationwide surveillance of antimicrobial susceptibility against Neisseria gonorrhoeae from male urethritis in Japan, 2016-2017.

Humans Male Neisseria gonorrhoeae Anti-Bacterial Agents / pharmacology Cefixime / pharmacology Ceftriaxone / therapeutic use Azithromycin / therapeutic use Spectinomycin / pharmacology Urethritis / drug therapy Japan / epidemiology Gonorrhea / drug therapy Anti-Infective Agents / therapeutic use Microbial Sensitivity Tests
Antimicrobial susceptibilities Japan Nationwide surveillance Neisseria gonorrhoeae

Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 08 06 2023
revised: 21 07 2023
accepted: 03 08 2023
medline: 18 9 2023
pubmed: 9 8 2023
entrez: 8 8 2023
Statut: ppublish

Résumé

Neisseria gonorrhoeae is one of the important pathogens of sexually transmitted infections. N. gonorrhoeae is rapidly becoming antimicrobial resistant, and there are few drugs that are effective in the initial treatment of gonorrhea. To understand the trends of antimicrobial susceptibility of N. gonorrhoeae, the Surveillance Committee of the Japanese Society of Infectious Diseases, the Japanese Society for Chemotherapy, and the Japanese Society of Clinical Microbiology conducted the third nationwide antimicrobial susceptibility surveillance of N. gonorrhoeae isolated from male urethritis. The specimens were collected from male patients with urethritis at 30 facilities from May 2016 to July 2017. From the 159 specimens collected, 87 N. gonorrhoeae strains were isolated, and 85 were tested for susceptibility to 21 antimicrobial agents. All strains were non-susceptible to penicillin G. Seven strains (8.2%) were β-lactamase-producing strains. The rates of susceptibility to cefixime and cefpodoxime were 96.5% and 52.9%, respectively. Three strains were non-susceptible with a minimum inhibitory concentration (MIC) of 0.5 mg/L for cefixime. None of the strains were resistant to ceftriaxone or spectinomycin. The susceptibility rate for ciprofloxacin was 23.5% (20 strains), and no strains showed intermediate susceptibility. The susceptibility rate against azithromycin was 81.2%, with one strain isolated with a MIC of 8 mg/L against azithromycin. The results of this surveillance indicate that ceftriaxone and spectinomycin, which are currently recommended for gonococcal infections in Japan, appear to be effective. It will be necessary to further expand the scale of the next surveillance to understand the current status of drug-resistant N. gonorrhoeae in Japan.

Identifiants

DOI: 10.1016/j.jiac.2023.08.003 PMID: 37553046
pubmed: 37553046
pii: S1341-321X(23)00185-X
doi: 10.1016/j.jiac.2023.08.003
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cefixime 97I1C92E55
Ceftriaxone 75J73V1629
Azithromycin 83905-01-5
Spectinomycin 93AKI1U6QF
Anti-Infective Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1011-1016

Informations de copyright

Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Satoshi Takahashi received speaker honoraria from MSD K.K., Fujirebio Inc. and research funding from Shino-Test Corporation, Roche Diagnostic K.K., Fujirebio Inc., and Abbott Japan Co., Ltd. Shingo Yamamoto received speaker honoraria from MSD K.K., Fuso Pharmaceutical Industries, Ltd., Daiichi Sankyo Co., Ltd. and scholarship donations from Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd. and research funding from Takeda Pharmaceutical Co., Ltd. Tetsuya Matsumoto received speaker honoraria from MSD K.K., Pfizer Japan Inc., and Kyorin Pharmaceutical Co., Ltd., and research funding from Kewpie Corporation., Biofermin Pharmaceutical Co., Ltd. Hiroyuki Nishiyama received research funding from Chugai Pharmaceutical Co., Ltd. Kazumasa Matsumoto received research funding from Sysmex Corporation. Junichi Inokuchi received research funding from Chugai Pharmaceutical Co., Ltd.

Auteurs

Mitsuru Yasuda (M)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. Electronic address: yasuda7jpe@sapmed.ac.jp.

Satoshi Takahashi (S)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.

Jun Miyazaki (J)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan; Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Koichiro Wada (K)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Faculty of Medicine, Shimane University, Izumo, Japan; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Kanao Kobayashi (K)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Chugoku Rosai Hospital, Hiroshima, Japan.

Masahiro Matsumoto (M)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, University of Occupational and Environmental Health, Japan, Fukuoka, Japan.

Hiroshi Hayami (H)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Blood Purification Center, Kagoshima University Hospital, Kagoshima, Japan.

Shingo Yamamoto (S)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Hyogo College of Medicine, Nishinomiya, Japan.

Hiroshi Kiyota (H)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan; Department of Urology, School of Medicine, The Jikei University Katsushika Medical Center, Tokyo, Japan.

Junko Sato (J)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.

Tetsuya Matsumoto (T)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.

Hiroshi Yotsuyanagi (H)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.

Hideaki Hanaki (H)

Research Center for Anti-infectious Drugs, Kitasato Institute for Life Science, Kitasato University, Tokyo, Japan.

Naoya Masumori (N)

Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan.

Yoshiki Hiyama (Y)

Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan.

Hiroyuki Nishiyama (H)

Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Takahiro Kimura (T)

Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Hiroki Yamada (H)

Department of Urology, School of Medicine, The Jikei University Katsushika Medical Center, Tokyo, Japan.

Kazumasa Matsumoto (K)

Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan.

Kiyohito Ishikawa (K)

Department of Urology, School of Medicine, Fujita Health University, Toyoake, Japan.

Yoshikazu Togo (Y)

Department of Urology, Hyogo College of Medicine, Nishinomiya, Japan.

Kazushi Tanaka (K)

Division of Urology, Kobe University, Kobe, Japan.

Takuya Sadahira (T)

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Junichi Inokuchi (J)

Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Ryoichi Hamasuna (R)

Department of Urology, University of Occupational and Environmental Health, Japan, Fukuoka, Japan.

Kenji Ito (K)

Ito Urology Clinic, Kitakyushu, Japan.

Hideo Hirayama (H)

Hirayama Urology Clinic, Kumamoto, Japan.

Kenji Hayashi (K)

Department of Urology, Tomakomai Urological Clinic, Hokkaido, Japan.

Yuichiro Kurimura (Y)

Department of Urology, Tomakomai Urological Clinic, Hokkaido, Japan.

Hitoshi Kadena (H)

Kadena Urology Clinic, Hiroshima, Japan.

Shin Ito (S)

IClinic, Sendai, Japan.

Yutaka Shiono (Y)

Aioi23Clinic, Yokohama, Japan.

Takahiro Maruyama (T)

Maruyama Urology Clinic, Nagoya, Japan.

Masayasu Ito (M)

Gifu Urological Clinic, Gifu, Japan.

Koichi Hatano (K)

Hatano Urology and Dermatology Clinic, Gifu, Japan.

Hirofumi Chokyu (H)

Chokyu Tenma Clinic, Himeji, Japan.

Hideari Ihara (H)

Ihara Clinic, Nishinomiya, Japan.

Satoshi Uno (S)

Hirajima Clinic, Okayama, Japan.

Koichi Monden (K)

Araki Urological Clinic, Kurashiki, Japan.

Teruhiko Yokoyama (T)

Yokoyama Urological Clinic, Okayama, Japan.

Motonori Kano (M)

Department of Urology, Kano Hospital, Kasuya-gun, Japan.

Shinichi Kaji (S)

Kaji Clinic, Fukuoka, Japan.

Motoshi Kawahara (M)

Kawahara Urology Clinic, Kagoshima, Japan.

Toru Sumii (T)

Sumii Clinic, Hiroshima, Japan.

Takanori Tojo (T)

Tomei Atsugi Hospital, Atsugi, Japan.

Takahide Hosobe (T)

Hosobe Clinic, Tokyo, Japan.

Kazuhiko Naito (K)

Naito Urology and Nephrology Clinic, Nagoya, Japan.

Shuichi Kawai (S)

Kawai Urology Clinic, Kitakyushu, Japan.

Hirofumi Nishimura (H)

Nishimura Urology Clinic, Kitakyushu, Japan.

Masanobu Izumitani (M)

Izumitani Fureai Clinic, Nagoya, Japan.

Mutsumasa Yoh (M)

Yoh Urology and Dermatology Clinic, Inazawa, Japan.

Masaru Matsumura (M)

Matsumura Urology Clinic, Kato, Japan.

Ryuji Fujita (R)

Nephrology and Urology Nishigawara Clinic, Okayama, Japan.

Kazuo Takayama (K)

Department of Urology, Takayama Hospital, Chikushino, Japan.

Makoto Hara (M)

Department of Urology, Tsujinaka Hospital, Kashiwa, Japan.

Shohei Nishi (S)

Nishi Urology and Dermatology Clinic, Kitakyushu, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The third nationwide surveillance of...
questionsmedicales.fr › Bactéries › Proteobacteria › Betaproteobacteria › Neisseriaceae › Neisseria › Neisseria gonorrhoeae › The third nationwide surveillance of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › The third nationwide surveillance of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Céphalosporines › Céfacétrile › Céfotaxime › Céfixime › The third nationwide surveillance of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Céphalosporines › Céfacétrile › Céfotaxime › Ceftriaxone › The third nationwide surveillance of...
questionsmedicales.fr › Composés chimiques organiques › Lactones › Érythromycine › Azithromycine › The third nationwide surveillance of...
questionsmedicales.fr › Glucides › Hétérosides › Aminosides › Spectinomycine › The third nationwide surveillance of...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies de l'urètre › Urétrite › The third nationwide surveillance of...
questionsmedicales.fr › Régions géographiques › Iles › Japon › The third nationwide surveillance of...
questionsmedicales.fr › Maladies urogénitales › Maladies génitales › Gonorrhée › The third nationwide surveillance of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › The third nationwide surveillance of...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › The third nationwide surveillance of...